Who is sponsoring NCT06133049?

NCT06133049 is sponsored by Bristol-Myers Squibb.

What condition does NCT06133049 study?

NCT06133049 studies Multiple Sclerosis.

What drugs are being tested in NCT06133049?

Interventions: Ozanimod, Select DMTs other than ozanimod, No DMTs.

What is the status of NCT06133049?

NCT06133049 is currently ACTIVE_NOT_RECRUITING.

Last reviewed 2023-11-15 · How we verify

A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants

NCT06133049 ACTIVE_NOT_RECRUITING

The purpose of this retrospective observational cohort study is to assess pregnancy and infant outcomes in three groups: the first is women with multiple sclerosis (MS) who were exposed to ozanimod during pregnancy; the second is women with MS exposed to select other disease-modifying therapies (DMTs) during pregnancy; the third is women with MS not exposed to any DMTs during pregnancy. This study will use data from a large US healthcare claims database.

Details

Lead sponsor	Bristol-Myers Squibb
Status	ACTIVE_NOT_RECRUITING
Enrolment	2961
Start date	Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Aug 31 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Multiple Sclerosis

Interventions

Ozanimod
Select DMTs other than ozanimod
No DMTs

Countries

United States